Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
107,800,271
-
Total 13F shares
-
30,132,601
-
Share change
-
+2,231,738
-
Total reported value
-
$454,629,539
-
Put/Call ratio
-
48%
-
Price per share
-
$15.09
-
Number of holders
-
127
-
Value change
-
+$33,366,992
-
Number of buys
-
77
-
Number of sells
-
49
Institutional Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q4 2016
As of 31 Dec 2016,
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) was held by
127 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
30,132,601 shares.
The largest 10 holders included
FMR LLC, VANGUARD GROUP INC, BlackRock Fund Advisors, BB BIOTECH AG, TimesSquare Capital Management, LLC, CITADEL ADVISORS LLC, JENNISON ASSOCIATES LLC, WASATCH ADVISORS INC, Hillhouse Capital Management, Ltd., and STATE STREET CORP.
This page lists
127
institutional shareholders reporting positions in this security
for the Q4 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.